Forecasting Individual Patients’ Best Time for Surgery in Colon-Rectal Cancer by Tumor Regression during and after Neoadjuvant Radiochemotherapy
Abstract
1. Introduction
2. Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
AJCC | American Joint Committee on Cancer |
CC | carrying capacity |
cCR | Clinical Complete Response |
CR | Complete recovery |
DOAJ | Directory of open access journals |
GL | Gompertz law |
GTV | Gross Tumor Volume |
LARC | Locally Advanced Rectal Cancer |
LD | Linear dichroism |
LL | Logistic law |
LNY | lymph node yield |
LR | Local Recurrence |
MDPI | Multidisciplinary Digital Publishing Institute |
MRI | Magnetic resonance imaging |
NACRT | Neoadjuvant chemoradiotherapy |
NACT | Neoadjuvant chemotherapy |
NAT | Neoadjuvant Therapy |
NCCN | National Comprehensive Cancer Network |
NOM | Non-operative management |
OS | Overall Survival |
PR | Partially responding |
QoL | Quality of Life |
RT | Radiotherapy |
TLA | Three letter acronym |
TME | Total Mesorectal Excision |
TNT | Total Neoadjuvant Therapy |
TRG | Tumor Regression Grade |
Appendix A
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.; Torre, L.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Glynne-Jones, R.; Wyrwicz, L.; Tiret, E.; Brown, G.; Rödel, C.; Cervantes, A.; Arnold, D.; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013, 24, iv22–iv40. [Google Scholar] [CrossRef] [PubMed]
- Baxter, N.N.; Morris, A.M.; Rothenberger, D.A.; Tepper, J.E. Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: A population-based analysis. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61, 426–431. [Google Scholar] [PubMed]
- Ha, Y.H.; Jeong, S.-Y.; Lim, S.-B.; Choi, H.S.; Hong, Y.S.; Chang, H.J.; Kim, D.Y.; Jung, K.H.; Park, J.G. Influence of preoperative chemoradiotherapy on the number of lymph nodes retrieved in rectal cancer. Ann. Surg. 2010, 252, 336–340. [Google Scholar] [CrossRef] [PubMed]
- Heald, R.; Husband, E.; Ryall, R. The mesorectum in rectal cancer surgery—The clue to pelvic recurrence? J. Br. Surg. 1982, 69, 613–616. [Google Scholar]
- Cunningham, D.; Atkin, W.; Lenz, H.; Lynch, H.; Minsky, B.; Nordlinger, B.; Starling, N. Colorectal cancer. Lancet 2010, 375, 1030–1047. [Google Scholar] [CrossRef]
- Chen, T.Y.-T.; Wiltink, L.M.; Nout, R.A.; Kranenbarg, E.M.-K.; Laurberg, S.; Marijnen, C.A.M.; van de Velde, C.J.H. Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: Report of a multicenter randomized trial. Clin Color. Cancer 2015, 14, 106–114. [Google Scholar] [CrossRef][Green Version]
- Benson, A.B.; Venook, A.P.; Al-Hawary, M.M.; Azad, N.; Chen, Y.J.; Ciombor, K.K.; Cohen, S.; Cooper, H.S.; Deming, D.; Garrido-Laguna, I.; et al. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2022, 20, 1139–1167. [Google Scholar] [CrossRef]
- Smith, J.J.; Chow, O.S.; Gollub, M.J.; Nash, G.M.; Temple, L.K.; Weiser, M.R.; Guillem, J.G.; Paty, P.B.; Avila, K.; Garcia-Aguilar, J.; et al. Organ Preservation in Rectal Adenocarcinoma: A phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer 2015, 15, 767. [Google Scholar]
- McCarthy, K.; Pearson, K.; Fulton, R.; J, H. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst. Rev. 2012, 12, CD008368. [Google Scholar] [CrossRef]
- Peeters, K.C.; Marijnen, C.A.; Nagtegaal, I.D.; Kranenbarg, E.K.; Putter, H.; Wiggers, T.; Rutten, H.; Pahlman, L.; Glimelius, B.; Leer, J.W.; et al. The TME trial after a median follow-up of 6 years: Increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann. Surg. 2007, 246, 693–701. [Google Scholar] [CrossRef] [PubMed]
- Kapiteijn, E.; Marijnen, C.A.; Nagtegaal, I.D.; Putter, H.; Steup, W.H.; Wiggers, T.; Rutten, H.J.; Pahlman, L.; Glimelius, B.; Van Krieken, J.H.J.; et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N. Engl. J. Med. 2001, 345, 638–646. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Bosset, J.F.; Collette, L.; Calais, G.; Mineur, L.; Maingon, P.; Radosevic-Jelic, L.; Daban, A.; Bardet, E.; Beny, A.; Ollier, J.C. Chemotherapy with preoperative radiotherapy in rectal cancer. N. Engl. J. Med. 2006, 355, 1114–1123. [Google Scholar] [CrossRef]
- Hofheinz, R.D.; Wenz, F.; Post, S.; Matzdorff, A.; Laechelt, S.; Hartmann, J.T.; Müller, L.; Link, H.; Moehler, M.; Kettner, E.; et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: A randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012, 13, 579–588. [Google Scholar] [CrossRef]
- Song, C.; Chung, J.H.; Kang, S.B.; Kim, D.W.; Oh, H.K.; Lee, H.S.; Kim, J.W.; Lee, K.W.; Kim, J.H.; Kim, J.S. Impact of tumor regression grade as a major prognostic factor in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: A proposal for a modified staging system. Cancers 2018, 10, 319. [Google Scholar] [CrossRef][Green Version]
- Li, Y.H.; Li, J.L.; Zhu, X.G.; He, J.Y.; Lin, L.M.; Lin, X.Y.; Tang, L.R.; Cai, Y. Associations of tumor regression grade with outcomes in patients with locally advanced rectal cancer treated with preoperative two-week course of radiotherapy. Oncotarget 2017, 8, 100165. [Google Scholar] [CrossRef]
- Vecchio, F.M.; Valentini, V.; Minsky, B.D.; Padula, G.D.; Venkatraman, E.S.; Balducci, M.; Miccichè, F.; Ricci, R.; Morganti, A.G.; Gambacorta, M.A.; et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62, 752–760. [Google Scholar] [CrossRef] [PubMed]
- Lee, S.; Oh, S.Y.; Kim, S.H.; Lee, J.H.; Kim, M.C.; Kim, K.H.; Kim, H.J. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer 2013, 13, 350. [Google Scholar] [CrossRef][Green Version]
- Portale, G.; Cavallin, F.; Valdegamberi, A.; Frigo, F.; Fiscon, V. Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio are not prognostic biomarkers in rectal cancer patients with curative resection. J. Gastrointest. Surg. 2018, 22, 1611–1618. [Google Scholar] [CrossRef]
- Kim, T.G.; Park, W.; Kim, H.; Choi, D.H.; Park, H.C.; Kim, S.H.; Cho, Y.B.; Yun, S.H.; Kim, H.C.; Lee, W.Y.; et al. Baseline neutrophil–lymphocyte ratio and platelet–lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy. Tumori J. 2019, 105, 434–440. [Google Scholar] [CrossRef]
- Hartley, A.; Ho, K.; McConkey, C.; Geh, J. Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: Analysis of phase II/III trials. Br. J. Radiol. 2005, 78, 934–938. [Google Scholar] [CrossRef] [PubMed]
- Appelt, A.; Pløen, J.; Harling, H.; Jensen, F.; Jensen, L.; Jørgensen, J.; Lindebjerg, J.; Rafaelsen, S.; Jakobsen, A. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: A prospective observational study. Lancet Oncol. 2015, 16, 919–927. [Google Scholar] [CrossRef] [PubMed]
- Glimelius, B. Optimal Time Intervals between Pre-Operative Radiotherapy or Chemoradiotherapy and Surgery in Rectal Cancer? Front. Oncol. 2014, 4, 50. [Google Scholar] [CrossRef][Green Version]
- Huang, C.W.; Su, W.C.; Yin, T.C.; Chen, P.J.; Chang, T.K.; Chen, Y.C.; Li, C.C.; Hsieh, Y.C.; Tsai, H.L.; Wang, J.Y. Time interval between the completion of radiotherapy and robotic-assisted surgery among patients with stage I–III rectal cancer undergoing preoperative chemoradiotherapy. PLoS ONE 2020, 15, e0240742. [Google Scholar] [CrossRef]
- Lichthardt, S.; Wagner, J.; Löb, S.; Matthes, N.; Kastner, C.; Anger, F.; Germer, C.T.; Wiegering, A. Pathological complete response due to a prolonged time interval between preoperative chemoradiation and surgery in locally advanced rectal cancer: Analysis from the German StuDoQ| Rectalcarcinoma registry. BMC Cancer 2020, 20, 49. [Google Scholar] [CrossRef]
- Ferini, G.; Valenti, V.; Tripoli, A.; Illari, S.; Molino, L.; Parisi, S.; Cacciola, A.; Lillo, S.; Giuffrida, D.; Pergolizzi, S. Lattice or oxygen-guided radiotherapy: What if they converge? Possible future directions in the era of immunotherapy. Cancers 2021, 13, 3290. [Google Scholar] [CrossRef] [PubMed]
- Ferini, G.; Castorina, P.; Valenti, V.; Illari, S.; Sachpazidis, I.; Castorina, L.; Marrale, M.; Pergolizzi, S. A Novel Radiotherapeutic Approach to Treat Bulky Metastases Even From Cutaneous Squamous Cell Carcinoma: Its Rationale and a Look at the Reliability of the Linear-Quadratic Model to Explain Its Radiobiological Effects. Front. Oncol. 2022, 12, 809279. [Google Scholar] [CrossRef]
- Dzutsev, A.; Goldszmid, R.S.; Viaud, S.; Zitvogel, L.; Trinchieri, G. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur. J. Immunol. 2015, 45, 17–31. [Google Scholar] [CrossRef]
- Castorina, P.; Castorina, L.; Ferini, G. Non-Homogeneous Tumor Growth and Its Implications for Radiotherapy: A Phenomenological Approach. J. Pers. Med. 2021, 11, 527. [Google Scholar] [CrossRef]
- SJ, M. The linear quadratic model: Usage, interpretation and challenges. Phys Med Biol 2018, 64, 01TR01. [Google Scholar]
- Castorina, P.; Ferini, G.; Martorana, E.; Forte, S. Tumor volume regression during and after radiochemotherapy: A macroscopic description. J. Pers. Med. 2022, 12, 530. [Google Scholar] [CrossRef] [PubMed]
- Gompertz, B. On the nature of the function expressive of the law of human mortality and a new mode of determining life contingencies. Philos. Trans. R. Soc. 1825, 115, 513–583. [Google Scholar]
- Royama, T. Analytical Population Dynamics; Springer Science & Business Media: Berlin, Germany, 2012; Volume 10. [Google Scholar]
- Meyer, P.S.; Ausubel, J.H. Carrying Capacity: A Model with Logistically Varying Limits. Technol. Forecast. Soc. Chang. 1999, 61, 209–214. [Google Scholar] [CrossRef]
- Wheldon, T. Mathematical Model in Cancer Research; Adam Hilger: Bristol, UK, 1988. [Google Scholar]
- Van den Begin, R.; Kleijnen, J.P.; Engels, B.; Philippens, M.; Asselen, B.; Raaymakers, B.; Reerink, O.; Ridder, M.; Intven, M. Tumor volume regression during preoperative chemoradiotherapy for rectal cancer: A prospective observational study with weekly MRI. Acta Oncol. 2018, 57, 723–727. [Google Scholar] [CrossRef][Green Version]
- Bostel, T.; Dreher, C.; Wollschläger, D.; Mayer, A.; König, F.; Bickelhaupt, S.; Schlemmer, H.; Huber, P.; Sterzing, F.; Bäumer, P.; et al. Exploring MR regression patterns in rectal cancer during neoadjuvant radiochemotherapy with daily T2- and diffusion-weighted MRI. Radiat. Oncol. 2020, 15, 171. [Google Scholar] [CrossRef]
- Mathur, P.; Smith, J.J.; Ramsey, C.; Owen, M.; Thorpe, A.; Karim, S.; Burke, C.; Ramesh, S.; Dawson, P.M. Comparison of CT and MRI in the pre-operative staging of rectal adenocarcinoma and prediction of circumferential resection margin involvement by MRI. Color. Dis. 2003, 5, 396–401. [Google Scholar] [CrossRef]
- Castorina, P.; Carco’, D. Nutrient supply, cell spatial correlation and Gompertzian tumor growth. Theory Biosci. 2021, 140, 197–203. [Google Scholar] [CrossRef]
- Vaghi, C.; Rodallec, A.; Fanciullino, R.; Ciccolini, J.; Mochel, J.P.; Mastri, M.; Benzekry, S. Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors. PLoS Comput. Biol. 2020, 16, e1007178. [Google Scholar] [CrossRef][Green Version]
- Parisi, S.; Ferini, G.; Cacciola, A.; Lillo, S.; Tamburella, C.; Santacaterina, A.; Bottari, A.; Brogna, A.; Ferrantelli, G.; Pontoriero, A.; et al. A non-surgical COMBO-therapy approach for locally advanced unresectable pancreatic adenocarcinoma: Preliminary results of a prospective study. La Radiol. Med. 2022, 127, 214–219. [Google Scholar] [CrossRef]
- Vadalà, R.; Santacaterina, A.; Sindoni, A.; Platania, A.; Arcudi, A.; Ferini, G.; Mazzei, M.; Marletta, D.; Rifatto, C.; Risoleti, E.; et al. Stereotactic body radiotherapy in non-operable lung cancer patients. Clin. Transl. Oncol. 2016, 18, 1158–1159. [Google Scholar] [CrossRef]
Patient | CC in cm |
---|---|
PR1 | |
PR2 | |
PR3 | <25.0 |
PR4 | |
CR1 | 1 |
CR2 | 1 |
CR3 | 1 |
CR4 | 1 |
Patient | Used/Total Number | CC |
---|---|---|
PR1 | ||
PR2 | ||
PR3 | ||
PR4 | ||
CR1 | 1 | |
CR2 | 1 | |
CR3 | 1 | |
CR4 | 1 |
Patient | Day Last Dose | Pred. Day | Pred./Obs. | Pred. Day | Pred./Obs. |
---|---|---|---|---|---|
PR1 | 15 | 23 | 28 | ||
PR2 | 16 | 22 | 28 | ||
PR3 | 16 | 21 | 28 | ||
PR4 | 14 | 21 | 28 | ||
CR1 | 16 | 21 | 28 | ||
CR2 | 9 | 24 | 28 | ||
CR3 | 9 | 20 | 25 | ||
CR4 | 23 | 24 | 27 |
Patient | CC in cm |
---|---|
PR1 | |
PR2 | |
PR3 | |
PR4 | |
CR1 | |
CR2 | |
CR3 | |
CR4 |
Patient | Used Data | CC |
---|---|---|
PR1 | ||
PR2 | 6 | |
PR3 | ||
PR4 | ||
CR1 | ||
CR2 | ||
CR3 | ||
CR4 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Martorana, E.; Castorina, P.; Ferini, G.; Forte, S.; Mare, M. Forecasting Individual Patients’ Best Time for Surgery in Colon-Rectal Cancer by Tumor Regression during and after Neoadjuvant Radiochemotherapy. J. Pers. Med. 2023, 13, 851. https://doi.org/10.3390/jpm13050851
Martorana E, Castorina P, Ferini G, Forte S, Mare M. Forecasting Individual Patients’ Best Time for Surgery in Colon-Rectal Cancer by Tumor Regression during and after Neoadjuvant Radiochemotherapy. Journal of Personalized Medicine. 2023; 13(5):851. https://doi.org/10.3390/jpm13050851
Chicago/Turabian StyleMartorana, Emanuele, Paolo Castorina, Gianluca Ferini, Stefano Forte, and Marzia Mare. 2023. "Forecasting Individual Patients’ Best Time for Surgery in Colon-Rectal Cancer by Tumor Regression during and after Neoadjuvant Radiochemotherapy" Journal of Personalized Medicine 13, no. 5: 851. https://doi.org/10.3390/jpm13050851
APA StyleMartorana, E., Castorina, P., Ferini, G., Forte, S., & Mare, M. (2023). Forecasting Individual Patients’ Best Time for Surgery in Colon-Rectal Cancer by Tumor Regression during and after Neoadjuvant Radiochemotherapy. Journal of Personalized Medicine, 13(5), 851. https://doi.org/10.3390/jpm13050851